MarketFriction

Unichem Laboratories Ltd

NSE UNICHEMLAB · BSE 506690 · Pharmaceuticals
₹535.05 -1.92%
NSE close2026-10-01
52 week range278.20 - 687.20
Market cap₹3,997 Cr.
P/E32.7
Price band 20% Delivery 36.6%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales416466432483507533587527579521575633
Expenses407435406443452448503504513476527563
Operating Profit93125405586842266454870
OPM %2.1%7%6%8%11%16%14%4.3%11%9%8%11%
Other Income679-119491497-372871116
Interest765457578797
Depreciation293227323231303231313130
Profit before tax-2273-1268276258-9-112931949
Tax %12%-0%3%74%9%6%8%16%10%10%42%15%
Net Profit-2473-1292255853-10-122641141
EPS in Rs-3.4810.40-18.370.293.508.227.52-1.49-1.6937.541.555.89
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,3336988151,1801,1041,2351,2701,3431,7852,1112,2022,308
Expenses1,1697389421,2541,1531,1441,1981,3891,6981,8462,0132,079
Operating Profit164-41-128-74-499172-4687265189229
OPM %12%-6%-16%-6%-4.5%7%6%-3.4%4.9%13%9%10%
Other Income151842,73591915047-0-2635260277
Interest33888561723213232
Depreciation39445167828491113123125125123
Profit before tax137972,548-58-485122-176-85155292350
Tax %21%-12%0%-59%25%33%-50%15%10%11%14%
Net Profit1081092,545-24-603433-202-94138253305
EPS in Rs11.9011.96361.82-3.38-8.554.874.70-28.72-13.3219.5335.9143.29
Dividend Payout %17%25%1%-118%-47%82%85%-14%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth5%12%18%7%
Compounded Profit Growth-3%25%35%-2%
Stock Price CAGR8%16%11%20%
Return on Equity11%0%2%3%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital181818141414141414141414
Reserves8499361,0452,6662,6062,5172,5432,6042,4212,4242,4372,703
Borrowings223698151200206119349314248460500
Other Liabilities264283359359323407436351444589659489
Total Liabilities1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,707
Fixed Assets4164034915788108708849901,2571,2521,3001,213
CWIP1232372502389233056849414712331100
Investments4114149019265503922642100
Other Assets5746207661,4731,3131,3951,2691,5711,7871,8982,2392,394
Total Assets1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,707
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7811268-112-3282033-260-8514-74
Cash from Investing Activity-52-85-1321,648-286-36-6610024163-242194
Cash from Financing Activity-51-3359-881-2-62-121191-81-1061842
Net Cash Flow-25-7-4655-616-78-1543275-29-65200
Free Cash Flow4-28-79-271-519-360-254-386-1230-142163
CFO/OP95%87%-237%89%424%-49%52%-350%160%23%4%6%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days586016512413512974142160131135137
Inventory Days171184397278278374518527414365418349
Days Payable114131297230182236202161193174164128
Cash Conversion Cycle116113265172231267390508382322389358
Working Capital Days8890174133165154163207207173159169
ROCE %9%15%9%128%-2%-2%2%1%-5%-0%6%4%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters70.21%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%
FIIs0.83%0.84%0.90%0.89%0.94%1.05%0.98%0.98%0.99%0.99%1.00%0.90%
DIIs10.00%10.46%11.26%11.57%11.65%11.63%11.32%10.92%10.74%10.73%10.63%10.46%
Public18.95%18.47%17.63%17.32%17.17%17.11%17.47%17.88%18.04%18.05%18.14%18.41%
No. of Shareholders21,58420,87721,17120,62120,37421,47221,62123,01023,57723,26723,38625,347

Fundamentals

Market Cap₹ 3,997 Cr.
Current Price₹ 568
Stock P/E32.7
Book Value₹ 386
ROCE4.13 %
ROE3.17 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)7%
Compounded Profit Growth (TTM)-2%
Consolidated figures.
Valuation
Market capRs 3,767 Cr
Enterprise valueRs 3,973 Cr
P/E (TTM)12.36x
Price to book1.39x
Price to sales1.63x
EV / EBITDA7.86x
EV / EBIT10.40x
EV / sales1.72x
Price to cash flow1034.91x
Earnings yield8.09%
P/E, 3-year average21.93x
P/B, 3-year average1.39x
P/E, 5-year average33.07x
P/B, 5-year average1.14x
Profitability
Operating margin (excl. other income)8.57%
Operating margin (incl. other income)20.40%
EBITDA margin21.90%
Pre-tax margin15.18%
Net profit margin13.21%
Net margin, latest quarter6.56%
ROE9.78%
ROCE10.57%
ROA6.95%
ROE, 3-year average3.85%
ROCE, 3-year average4.85%
ROA, 3-year average2.69%
ROE, 5-year average0.97%
ROCE, 5-year average2.00%
ROA, 5-year average0.58%
ROIC (approx.)11.30%
Tax rate13.52%
Other income / net worth9.58%
Growth
Sales growth (latest year)4.31%
Profit growth (latest year)83.86%
Sales CAGR, 3 years17.91%
Sales CAGR, 5 years12.26%
Profit CAGR, 5 years49.09%
Sales growth QoQ10.00%
Profit growth QoQ280.11%
Sales growth YoY (latest quarter)20.13%
Per share
EPS (TTM)Rs 43.29
EPS (latest year)Rs 35.91
EPS (latest quarter)Rs 5.89
EPS, 3-year averageRs 14.04
EPS, 5-year averageRs 3.62
Book value per shareRs 385.97
Sales per shareRs 327.80
Cash flow per shareRs 0.52
Free cash flow per shareRs 23.15
Dividend per share, 5-year averageRs 4.00
Dividends
Dividend payout, 5-year average85.18%
Efficiency
Asset turnover0.59x
Fixed asset turnover1.82x
Inventory turnover1.26x
Inventory days289 days
Debtor days137 days
Debtors turnover2.66x
Creditor days128 days
Cash conversion cycle358 days
Working capital days169 days
Leverage
Total debtRs 500 Cr
Cash and bankRs 295 Cr
Net debtRs 205 Cr
Debt to equity0.18x
Net debt / EBITDA0.41x
Interest coverage12.06x
Current ratio (filing 2026-03-31)2.48x
Quick ratio (filing 2026-03-31)1.38x
Trade payables (filing 2026-03-31)Rs 357 Cr
Owners' fund to total sources73.31%
Debt to assets13.49%
Cash flow
Cash from Operating Activity (latest year)Rs 4 Cr
Cash from Investing Activity (latest year)Rs 194 Cr
Cash from Financing Activity (latest year)Rs 2 Cr
Net Cash Flow (latest year)Rs 200 Cr
Free cash flow (latest year)Rs 163 Cr
FCFE (approx.: FCF + change in debt)Rs 203 Cr
Cash from ops / profit, 5 years-2.61x
Sales to cash flow604.90x
Statement figures
Net sales (TTM)Rs 2,308 Cr
Net sales (latest year)Rs 2,202 Cr
Sales (latest quarter)Rs 633 Cr
Operating profit excl. other income (latest year)Rs 189 Cr
Operating profit (latest quarter)Rs 70 Cr
Other income (TTM)Rs 277 Cr
EBITDA (TTM)Rs 505 Cr
PBDT (TTM)Rs 474 Cr
Profit before tax (TTM)Rs 350 Cr
Tax (latest year)Rs 40 Cr
Net profit (TTM)Rs 305 Cr
Net profit (latest year)Rs 253 Cr
Net profit (latest quarter)Rs 41 Cr
Depreciation (TTM)Rs 123 Cr
Depreciation (latest quarter)Rs 30 Cr
Interest (TTM)Rs 32 Cr
Cost of goods sold (latest year)Rs 1,230 Cr
Total expenditure (latest year)Rs 2,013 Cr
Total income (latest year)Rs 2,462 Cr
Share capitalRs 14 Cr
ReservesRs 2,703 Cr
Shareholders' fundsRs 2,717 Cr
Total assetsRs 3,707 Cr
Net blockRs 1,213 Cr
Capital work in progressRs 100 Cr
InvestmentsRs 0 Cr
ReceivablesRs 829 Cr
InventoryRs 975 Cr
Other liabilitiesRs 489 Cr
Shares outstanding (crore)7.04
Ownership
Promoter holding70.22% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 12.4 is at the 24th percentile of its own 5.5-year range (median 23.2, low 0.5, high 87.5).
P/B 1.39 is at the 70th percentile (median 0.99).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodUNICHEMLABNifty 50Difference
1 week-3.2%-2.8% -0.4 pts
1 month-3.8%-6.8% +3.0 pts
3 months+13.1%-7.6% +20.7 pts
6 months+82.3%+0.4% +81.9 pts
1 year+9.9%-9.9% +19.9 pts
2 years-16.5%-13.6% -3.0 pts
3 years+28.0%+14.2% +13.8 pts
5 years+94.4%+27.9% +66.5 pts
4 mutual fund schemes hold about ₹339 Cr. Over three months 0 bought more and 1 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Small Cap Fund0.66%276 -7%
DSP Healthcare Fund1.64%63 -1%
Bandhan BSE Healthcare Index Fund0.07%0 +2%
Motilal Oswal BSE 1000 Index Fund0.01%0

Red flags

F-score 5 of 8
explainWeak cash conversion Cash from operations was 4% of net profit over the last 3 years
lookProfit leans on other income Other income was 89% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹633 Cr +20.1% vs Jun 2025. Net profit ₹41 Cr +510.0%.
Against our estimate for Jun 2026: sales +22.8%, profit +102421.1% in line. Our estimate for Sep 2026: sales Rs 631 Cr, profit Rs 26 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2022-08-01Annual General Meeting/Dividend - Rs 4 Per Share
2021-07-22 Annual General Meeting/Dividend - Rs 4 Per Share
2020-08-20 Annual General Meeting/Dividend - Rs 4 Per Share
2019-07-18 Annual General Meeting/Dividend - Rs 4 Per Share
2018-07-19 Annual General Meeting/Dividend- Rs 5 Per Share
2018-02-15 Buyback
2017-07-13 Annual General Meeting/Dividend - Rs 3/- Per Share
2016-07-14 Annual General Meeting
2016-03-17 Interim Dividend - Rs 2/- Per Share
2015-07-02Annual General Meeting/Dividend - Rs 2/- Per Share
2014-07-03Annual General Meeting/Dividend Rs 4/- Per Share
2014-01-23Interim Dividend Rs.4/- Per Share (Purpose Revised)
2013-07-11Annual General Meeting/Dividend Rs 4.50 Per Equity Share
2012-09-13Annual General Meeting And Dividend Rs.3/- Per Share
2011-07-14Annual General Meeting And Dividend Rs.2.80 Per Share
2010-10-21Interim Dividend Rs.3/- Per Share And Face Value Split From Rs.5/- To Rs.2/- (Purpose Revised)0.4000
2010-09-08Annual General Meeting
2010-05-142nd Interim Dividend-Rs.7/- Per Share (Purpose Revised)
2009-10-27Interim Dividend
2009-07-09Agm/Div-Rs.5/- Per Share
2008-10-29Interim Dividend - 60% Purpose Revised
2008-07-10Agm/Dividend - 100%
2007-07-06Agm
2007-03-16Int Div-Rs.5/- Per Sh Purpose Revised
2006-07-13Agm/Dividend-100%
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Unichem Laboratories Ltd?

Unichem Laboratories Ltd (UNICHEMLAB) has a market capitalisation of Rs 3,997 Cr. at the 2026-10-01 close.

What is the P/E ratio of Unichem Laboratories Ltd?

Unichem Laboratories Ltd trades at a P/E of 32.7 on trailing twelve-month profit, at the 2026-10-01 close.

What were Unichem Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Unichem Laboratories Ltd sales was Rs 633 Cr (+20.1% vs Jun 2025) and net profit was Rs 41 Cr.

What is the 52-week high and low of Unichem Laboratories Ltd?

The 52-week high is Rs 687.20 and the 52-week low is Rs 278.20.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03